New analyses of tramiprosate data presented at CTAD

9 December 2016
2019_biotech_test_vial_discovery_big

Closely-held US biotech firm Alzheon has presented new analyses of previous Phase III data for tramiprosate, an investigational amyloid anti-aggregation agent and the active molecule of prodrug ALZ-801, in an oral presentation at the 9th annual Clinical Trials on Alzheimer’s Disease (CTAD) conference in San Diego.

  • The new results strengthen Alzheon's precision medicine approach which identifies distinct biological phenotypes in Alzheimer’s disease (AD) patients.
    • These phenotypes were described in the recently-published analyses of the tramiprosate Phase III data, showing that AD patients who carry two e4 alleles of apolipoprotein E gene (APOE4/4 homozygotes) respond with the largest clinical benefits.
  • The results show tramiprosate’s largest efficacy signals on cognition and function in APOE4/4 homozygous patients with mild AD, defined as MMSE of 22 and higher.

Alzheon also presented a poster on the Phase I clinical studies and bridging data for ALZ-801, an optimized prodrug of tramiprosate, that support the pivotal clinical program planned to begin in 2017, which will evaluate ALZ-801 as a potential disease-modifying treatment for APOE4/4 homozygous patients at the mild stage of Alzheimer’s disease.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology